Novan Announces Corporate Update
Conference Call and Webcast

MORRISVILLE, N.C., July 25, 2017 -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, Aug. 2, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States and Canada) or +1 (703) 318-2240 (international). The conference ID for the live call is 61221795. A live webcast will be accessible from the Events page of the Company’s website at http://Events.Novan.com. The webcast will be archived on the Company’s website for 90 days following the live call.

About Novan

Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.

For more information, visit the Company’s website at www.Novan.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, our potential financing opportunities and partners, as well as our expected uses of cash and cost-savings initiatives, and the future prospects of our business, including management succession, operating activities and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research or trials; the lengthy and unpredictable nature of the U.S. Food and Drug Administration’s drug approval process; whether we will be able to enter into strategic arrangements or obtain adequate funding to support
our operations and initiatives on acceptable terms, or at all; our ability to implement and realize anticipated benefits from any adjustments to our business, including headcount reductions and other cost-saving measures; our ability to modify, streamline or reposition our manufacturing infrastructure and associated capabilities on financial and operational terms that are acceptable; the ability to attract and retain senior management and key employees and other risks and uncertainties described in our annual report filed with the Securities and Exchange Commission, or SEC, on Form 10-K for the twelve months ended Dec. 31, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

CONTACT:

(Investors)

Novan, Inc.

919-627-6847

investors@novan.com

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)

(Investors)